Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.
The company have developed a non-invasive blood test for early lung cancer detection, using our patented CIZ1B biomarker technology.
The CIZ1B Biomarker
A Breakthrough in Early Diagnosis
Cizzle has pioneered a groundbreaking approach to lung cancer detection with the CIZ1B biomarker test—a non-invasive diagnostic tool designed to identify lung cancer at its earliest and most treatable stage.
By addressing a critical gap in current diagnostics, this test has the potential to transform patient outcomes by enabling early intervention, when curative surgical resection is still an option.
Scientific Foundations:
Backed by two decades of grant-funded research led by Professor Dawn Coverley and her team at the University of York, this innovative technology is built on a deep understanding of the CIZ1 protein, and its role in stabilising the patterns of gene expression that are established in normal cells and tissues.
Their research shows that CIZ1 normally functions as part of the nuclear structures that dampen the expression of some genes. They found that altered forms of the CIZ1 protein lead to undisciplined cells, and that this is linked with the early stages of cancer.
Detect Early. Save Lives.
